Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC (PER®), is approved by the California Board of Registered Nursing, Provider #16669, for 1.50 contact hours.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-20-377-H01-P. The activity is available for CE credit through November 23, 2021.

Acknowledgment of Support

This activity is supported by educational grants from Eisai Inc., and Merck & Co., Inc.

Medical Crossfire®: How Can We Optimize Multidisciplinary Management of Patients with Advanced Endometrial Cancer?

Release Date: November 23, 2020
Expiration Date: Novemer 23, 2021

Activity Overview

Medical Crossfire®, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts engage in spirited discussions and debates on a particular clinical topic. In this activity, 5 key thought leaders explore the latest data regarding current, new, and emerging therapeutic strategies—including combined use of an immune checkpoint inhibitor and a tyrosine kinase inhibitor—for the management of endometrial cancer. This lively multidisciplinary discussion will place new developments into clinical context to help you optimize care for your patients with endometrial cancer.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Eisai Inc., and Merck & Co., Inc.
 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward gynecologic oncologists, medical oncologists, oncology nurses, and health system pharmacists who treat or manage women with endometrial cancer. Other allied healthcare professionals involved in the treatment and management of endometrial cancer will also be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Assess the impact of advances in understanding of endometrial cancer biology on diagnosis, prognosis, and treatment of patients with endometrial cancer.
  • Outline the biological rationale for available and emerging treatment strategies for endometrial cancer.
  • Evaluate clinical trial data regarding safety and efficacy of novel treatment strategies or combinations for endometrial cancer.
  • Apply strategies that incorporate the multidisciplinary team to clinical scenarios for patients with endometrial cancer.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Namissa, PharmD, BCPS; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

Faculty

 

Ursula A. Matulonis, MD
Ursula A. Matulonis, MD
Director and Chief, Division of Gynecologic Oncology
Susan F. Smith Center for Women’s Cancers
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:Consultant: Merck

Lisa Arvine, NP
Lisa Arvine, NP
Nurse Practitioner
Department of Gynecologic Oncology
Dana-Farber Cancer Institute
Boston, MA

Disclosures:No relevant financial relationships with commercial interests to disclose

Susana Campos, MD, MPH
Susana Campos, MD, MPH
Physician
Department of Medical Oncology
Dana-Farber Cancer Institute
Assistant Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures:Consultant: Eisai, AstraZeneca
 

Don S. Dizon, MD, FACP, FASCO
Don S. Dizon, MD, FACP, FASCO
Professor of Medicine
Brown University
Director of Women’s Cancers
Lifespan Cancer Institute
Director of Medical Oncology
Rhode Island Hospital
Providence, RI

Disclosures:Grant Research Support: Bristol Myers Squibb; Consultant: AstraZeneca, Clovis Oncology, Regeneron
 

Judith A. Smith, B.S, Pharm.D., BCOP, CPHQ, FCCP, FHOP, FISOPP
Judith A. Smith, B.S, Pharm.D., BCOP, CPHQ, FCCP, FHOP, FISOPP
Professor & Director of Women’s Health Integrative Medicine
Research Program
Division of Gynecologic Oncology
Department of Obstetrics, Gynecology & Reproductive Sciences
UTHealth McGovern Medical School
Oncology Clinical Pharmacy Specialist
UTHealth- Memorial Hermann Cancer Center – TMC
Houston, TX

Disclosures:No relevant financial relationships with commercial interests to disclose

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By